PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Symptom | |diabetes |
| Sentences | 526 |
| PubMedID- 22827862 | These figures are reflected in important obesity-related complications, such as hypertension, hyperlipidemia, and type 2 diabetes, all leading causes of cardiovascular disease.2 type 2 diabetes affects 8.3% of the u.s. population (27% of u.s. residents aged 65 years and older), whereas 35% of u.s. adults have fasting glucose and glycosylated hemoglobin (hba1c) levels in the prediabetic range.3 thus, it is of great importance to characterize contributing etiological factors in order to effectively counteract the obesity and diabetes epidemics. |
| PubMedID- 26246459 | Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the american heart association and the american diabetes association. |
| PubMedID- 26555141 | Associations were examined after adjusting for individual demographic (age, gender, ethnicity), medical (hypertension, diabetes, hyperlipidaemia, history of cardiovascular disease cvd) and life-style (alcohol and smoking status) risk factors. |
| PubMedID- 21270271 | Patients with type 1 diabetes have increased levels of subclinical cardiovascular disease, as measured by carotid intima-media thickness (imt), a measure of atherosclerosis. |
| PubMedID- 26251229 | Using an interrupted time series design and segmented regression, we estimated changes in monthly prescribing rates for thiazolidinediones among all and prevalent diabetes patients with and without cardiovascular disease history (cv history). |
| PubMedID- 24082791 | The relative risk of cardiovascular disease for persons with diabetes is double or more than that of persons without diabetes,14 although the absolute risk of cardiovascular disease varies around the world. |
| PubMedID- 22305579 | Conclusions: time-dependent variation of fpg was a strong predictor of all-cause, expanded, and nonexpanded cardiovascular disease-related mortality in patients with type 2 diabetes, suggesting that glucose variation may become a measure in clinical practice for the goal in the management of these patients. |
| PubMedID- 26223257 | The incidence of cardiovascular disease in people with diabetes is more than double that in people without diabetes, and the mortality rate after a first myocardial infarction is much higher in people with diabetes . |
| PubMedID- 22228612 | Dyslipidaemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. |
| PubMedID- 25612994 | We describe a concurrent manifestation of emphysematous pyelonephritis and ischaemic colitis in a 51-year-old diabetic woman and conclude that the colitis was due to pressure from a large retroperitoneal mass and sepsis complications combined with underlying peripheral vascular disease because of diabetes mellitus and hypertension. |
| PubMedID- PMC4033993 | However, use of aspirin in primary prevention of cardiovascular disease, or in patients with diabetes mellitus, or in those with peripheral vascular disease is not supported by the current evidence. |
| PubMedID- 23326760 | In this trial 11 140 patients with type 2 diabetes and a history of macrovascular disease or another risk factor were randomly assigned to intensive glucose control (target <6.5%) or standard glucose control (target hba1c >7%). |
| PubMedID- 24369540 | Until now, most common additive risk factors for vascular disease in people with diabetes have been demonstrated as hyperglycaemia, insulin resistance, dyslipidaemia, hypertension, tobacco use, and obesity ; however, the interaction of the factors and molecular signalling pathways have not been fully elucidated. |
| PubMedID- 21875885 | We evaluated the differences between low and high chocolate consumption on outcomes such as diabetes, incidence of cardiovascular disease, cardiovascular mortality, coronary heart disease, incidence of stroke, and deaths from stroke. |
| PubMedID- 20671994 | Their efficacy in patients with type 2 diabetes in the absence of cardiovascular disease has not been established through clinical trials, although they are widely recommended. |
| PubMedID- 24406095 | However, the early treatment diabetic retinopathy study report 14 results from 1992 support treatment with asa in patients with diabetes at increased risk of cardiovascular disease and found no increased risk of retinal bleeding associated with the use 6. |
| PubMedID- 19875998 | The impact of obesity on cardiovascular disease (cvd) outcomes in patients with type 2 diabetes mellitus (t2dm) and established coronary artery disease (cad) is controversial; whether bmi and/or waist circumference correlate with atherothrombotic risk factors in such patients is uncertain. |
| PubMedID- 24049653 | It was determined in many multiple independent longitudinal studies that the hp genotype is an independent determinant of the risk of incident cardiovascular disease in individuals with diabetes mellitus (dm) . |
| PubMedID- 24616659 | The consequences of poor glucose homeostasis are well-known: hyperglycemia associated with uncontrolled diabetes can lead to cardiovascular disease, neuropathy and nephropathy, while hypoglycemia can lead to convulsions, loss of consciousness, coma, and even death. |
| PubMedID- 22853195 | Although food restriction is a standard therapy in type ii diabetic patients, no long-term large-scale study of intentional weight loss has been adequately powered to examine cardiovascular disease end points in patients with diabetes . |
| PubMedID- 20934769 | Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus. |
| PubMedID- 26481300 | Book review: diabetes in cardiovascular disease: a companion to braunwald's heart disease. |
| PubMedID- 23227510 | A current model for predicting the risk of cardiovascular diseases in patients with type 2 diabetes mellitus. |
| PubMedID- 24625012 | In addition, diabetes is associated with cardiovascular disease, which is an important contributor to the overall morbidity and mortality associated with this condition. |
| PubMedID- 22347652 | The mechanisms underlying the increased risk of cardiovascular disease associated with diabetes mellitus (dm) are not fully defined. |
| PubMedID- 23238663 | Dietary interventions that could reduce the risk of development of cardiovascular disease (cvd) in patients with type 2 diabetes mellitus (t2dm) would clearly be advantageous instead of expensive pharmacological treatments. |
| PubMedID- 25197673 | Objective: to investigate the potential benefits of acarbose treatment on cardiovascular disease (cvd) in patients with type 2 diabetes by using nationwide insurance claim dataset. |
| PubMedID- 25784087 | Association of parental history of diabetes with cardiovascular disease risk factors in children with type 2 diabetes. |
| PubMedID- 22525426 | The prevalence of atherosclerotic cardiovascular disease is higher in patients with type 2 diabetes, a disorder characterized by hyperinsulinemia and insulin resistance. |
| PubMedID- 24678413 | The exclusion criteria were subjects who had diabetes mellitus, history of cardiovascular disease and heart failure, presence of cerebrovascular disease, arrhythmias (atrial fibrillation), history of ophthalmic surgery, cataract which affects the corrected visual acuity, glaucoma, and vitreous and retinal diseases. |
| PubMedID- 26078757 | Opg is associated with poor glycaemic control and cardiovascular disease (cvd) in patients with type 1 diabetes, compatible with the hypothesis that opg is associated with the development of diabetic vascular complications . |
| PubMedID- 26341126 | For example, these challenges stem from people with diabetes most frequently dying of cardiovascular diseases or renal failure, and the physicians who record and determine the causes of death may miss and underestimate the contributions of diabetes on death . |
| PubMedID- 22536510 | Subjects with diabetes and clinical evidence of cardiovascular diseases or receiving antacids, lipid-lowering drugs, or antioxidant supplements were excluded from the study to avoid possible interferences on pon1 activity and plasma lipids. |
| PubMedID- 25393017 | Advanced glycation end products (ages) are thought to contribute to the abnormal lipoprotein profiles and increased risk of cardiovascular disease in patients with diabetes and renal failure. |
| PubMedID- 23008738 | However, the results varied by population (healthy adults, adults at cardiovascular disease risk, adults with type 2 diabetes, etc.) |
| PubMedID- 26246173 | Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the american heart association and the american diabetes association. |
| PubMedID- 21934489 | Although perturbations of haemostatic markers have been shown to be associated with macrovascular disease in patients with type 2 diabetes, it is unclear whether these are primarily due to endothelial dysfunction or a result of inflammation. |
| PubMedID- 23250802 | Objective: to examine the bmi-stratified associations between diabetes and the risks of all-cause death, cardiovascular disease (cvd) death, and cancer death. |
| PubMedID- 24199160 | In the phase ii effect of the dual peroxisome proliferator-activated receptor-α/γagonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (synchrony) study, aleglitazar showed dose-dependent metabolic benefits, including significant dose-dependent reduction in hba1c of -0.36% (4 mmol/mol, 50 µg; p=0.048) to -1.35% (15 mmol/mol, 600 µg; p<0.0001) in 16 weeks of treatment compared to placebo. |
| PubMedID- 22569118 | Background: although most deaths among patients with type 2 diabetes (t2d) are attributable to cardiovascular disease, modifiable cardiovascular risk factors appear to be inadequately treated in medical practice. |
| PubMedID- 20920303 | If hypertension and chronic renal disease co-exist, as is common in patients with diabetes mellitus, the risk of cardiovascular disease is heightened. |
| PubMedID- 23978254 | From february 2002 to january 2005, we enrolled 135 consecutive asymptomatic patients (74 male; mean age, 63 ± 9 years) with type 2 diabetes without a history of cardiovascular disease. |
| PubMedID- 21929289 | Background: the mechanisms responsible for the accelerated cardiovascular disease in diabetes, as well as the increased hypertrophic effects of angiotensin ii (ang ii) under hyperglycemic condition, are not very clear. |
| PubMedID- 25018969 | Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the american heart association and the american diabetes association. |
| PubMedID- 24357694 | A novel and potentially translational finding of this investigation is the notion that the type of glucose biomarker measurement has some intrinsic relationship to metabolic memory in understanding the natural micro- and macrovascular disease progression in patients with type 1 diabetes (fig. |
| PubMedID- 20929996 | Therefore, the aim of our study was to evaluate whether repeated episodes of hypoglycemia represent an aggravating factor for macrovascular disease in subjects with type 1 diabetes through early atherosclerosis-vascular assessment. |
| PubMedID- 25149070 | Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the fenofibrate intervention and event lowering in diabetes (field) study. |
| PubMedID- 26426904 | The nature of comorbid cardiovascular disease, concordant with diabetes, probably explains its augmenting effect observed for sbp. |
| PubMedID- 23113179 | Therefore, higher rates of cardiovascular disease because of type 2 diabetes, among people with lower socioeconomic characteristics are expected and demonstrated in several studies (8, 20). |
| PubMedID- 23738569 | Data were recorded on hypertension, diabetes, a history of cerebral vascular disease and other chronic diseases. |